Search results for " hepatitis C virus"

showing 10 items of 30 documents

Occult hepatitis B virus infection

2000

Many studies have shown that hepatitis B virus infection may also occur in hepatitis B surface antigen-negative patients. This occult infection has been identified both in patients with cryptogenic liver disease and in patients with hepatitis C virus-related chronic hepatitis, and much evidence suggests that it may be a risk factor of hepatocellular carcinoma development. However several aspects of this occult infection remain unclear such as its prevalence and the factor(s) involved in the lack of circulating hepatitis B surface antigen. Moreover, it is uncertain whether the occult hepatitis B virus infection may contribute to chronic liver damage, considering that it is usually associated…

MaleACUTE VIRAL-HEPATITISPOSTTRANSFUSION HEPATITISHBV SURFACE-ANTIGENComorbidityHBV genome HBsAg-negative liver DNA liver diseasemedicine.disease_causeSeverity of Illness IndexSEROLOGICAL MARKERS; TRANSPLANT RECIPIENTS; POSTTRANSFUSION HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR-CARCINOMA; HBV SURFACE-ANTIGEN; ACUTE VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; POLYMERASE CHAIN-REACTION; occult hepatitis B virus infectionLiver diseaseCHRONIC LIVER-DISEASEHEPATOCELLULAR-CARCINOMAChronic/diagnosis* Hepatitis BDifferential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis Bhbsag-negative; hbv genome; liver disease; liver dnaIncidenceHepatocellular/diagnosis CarcinomaLiver NeoplasmsGastroenterologyHepatitis CHepatitis BPOLYMERASE CHAIN-REACTIONPrognosisChronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexCarcinoma Hepatocellular/diagnosis Carcinoma Hepatocellular/epidemiology* Comorbidity DNA Viral/analysis Diagnosis Differential Disease Progression Female Hepatitis B Surface Antigens/analysis* Hepatitis B Chronic/diagnosis* Hepatitis B Chronic/epidemiology* Humans Incidence Liver Neoplasms/diagnosis Liver Neoplasms/epidemiology* Male Prognosis Risk Assessment Severity of Illness IndexHepatocellular carcinomaDisease Progressionhbv genomeFemaleliver diseaseCarcinoma HepatocellularTRANSPLANT RECIPIENTSRisk AssessmentDiagnosis Differentialoccult hepatitis B virus infectionHepatitis B ChronicViral/analysis DiagnosismedicineHumansRisk factorHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryCarcinomaHEPATITIS C VIRUShbsag-negativeliver dnamedicine.diseaseOccultVirologyHepatocellular/epidemiology* Comorbidity DNASEROLOGICAL MARKERSViral replicationImmunologyDNA Viralbusiness
researchProduct

Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".

2022

Dear Editor, Elhence et al.1 assessed the retreatment outcomes of direct‐ acting antivirals (DAAs) therapy failure in a cohort of 40 patients with chronic hepatitis C (HCV) and previous virological failure (VF) to DAAs. The results were remarkable, with an overall sustained virologic response (SVR) of 100% in patients who completed retreatment with sofosbuvir and velpatasvir (with/without ribavirin). We compared these results with our experience in the multicenter HCV‐ Surveillance Cohort Long‐Term Toxicity Antivirals (HCV‐SCOLTA) cohort, an active pharmacovigilance system supported by the CISAI group (Italian Coordinators for the Study of Allergies and HIV Infection). Since 2012, Italian i…

MaleAntiviral agentSustained Virologic ResponseAnti-hepatitis C virus DAA (directly acting antivirals); Antiviral agents; Hepatitis C virus; Hepatitis virus; Virus classification; Antiviral Agents; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Medication Adherence; Middle Aged; Sustained Virologic ResponseHepatitis C virusTreatment outcomeHepacivirusmedicine.disease_causeAntiviral AgentsHepatitis viruMedication AdherenceChronic hepatitisVirologyMedicineHumansIn patientChronicAnti-hepatitis C virus DAA (directly acting antivirals)Virus classificationHepatitis virusVirus classificationHepatitis C virusbusiness.industryAntiviral therapyHepatitis C ChronicMiddle AgedHepatitis CVirologyHepatitis virusInfectious DiseasesItalyFemaleHepatitis C virubusinessDirect actingJournal of medical virology
researchProduct

Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.

2005

Hepatitis C virus is not cleared after primary infection in 50-85% of subjects exposed to hepatitis C virus. Anti-viral treatment during the early phase of infection significantly enhances the likelihood of a sustained clearance of hepatitis C virus. Although, a variety of autoimmune-related side effects have been observed during interferon therapy for chronic hepatitis, immuno-mediated adverse reactions have not been reported during treatment of acute hepatitis C. We describe the case of a patient who developed acute hepatitis C virus infection and, while receiving pegylated interferon alpha-2b monotherapy, developed a severe polymyositis. This case illustrates the potential risk of autoim…

MaleHepatitis C virusHepacivirusAcute hepatitis CAlpha interferonAutoimmunityHepacivirusInterferon alpha-2medicine.disease_causeIFNPolymyositisPolyethylene GlycolAntiviral AgentsVirusPolyethylene GlycolsPegylated interferonInterferonmedicineHumansDrug CarrierCreatine KinasePolymyositiAntiviral AgentDrug CarriersHepaciviruHepatologybiologybusiness.industryGastroenterologyInterferon-alphaHepatitis CRecombinant ProteinMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CRecombinant ProteinsAcute hepatitis C; Hepatitis C virus; IFN; Polymyositis; Acute Disease; Antiviral Agents; Autoimmunity; Creatine Kinase; Drug Carriers; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymyositis; RNA Viral; Recombinant Proteins; GastroenterologyPolymyositisImmunologyAcute DiseaseRNA ViralbusinessHepatitis C virumedicine.drugHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period

2007

BACKGROUND & AIMS: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children. METHODS: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively. RESULTS: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon alpha. Ten years after putative exposure, the out…

MalePediatricsEpidemiologyInfectious Disease TransmissionCHILDRENHepacivirusmedicine.disease_causeGENOTYPES HCVRisk FactorsEpidemiologyPrevalenceVerticalChronicYoung adultChildHCV infection in childrenbiologyHepatitis C virus (HCV)Hepatitis CANTI-HCVHepatitis CItalyChild PreschoolHCVFemaleViral diseaseAdultmedicine.medical_specialtyEpidemiology of HCV infectionGenotypepediatricsHepatitis C virusSocio-culturaleEnzyme-Linked Immunosorbent AssayFlaviviridaeHCV vertical transmissionmedicineHumansBlood TransfusionSex DistributionPreschoolRetrospective StudiesEpidemiology of HCV infection; HCV infection in children; HCV vertical transmission; Hepatitis C virus (HCV); Adult; Blood Transfusion; Child; Child Preschool; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Infant; Infectious Disease Transmission Vertical; Italy; Male; Prevalence; Retrospective Studies; Risk Factors; Sex Distribution; HepatologyHepatologybusiness.industryHIVInfantRetrospective cohort studyHepatitis C AntibodiesHepatitis C Chronicmedicine.diseasebiology.organism_classificationHEPATITIS HCVInfectious Disease Transmission VerticalEl NiñoImmunologybusiness
researchProduct

Management of chronic hepatitis C in childhood: The impact of therapy in the clinical practice during the first 2 decades

2011

Background and aim: Treatment of chronic hepatitis C in children is controversial and its role in the clinical practice is unknown. We retrospectively investigated the impact of treatment in a large cohort of children with chronic hepatitis C over the past 20years. Methods: 376 hepatitis C virus RNApositive children were recruited consecutively in five Italian centres since 1990and followed for1–17years. Results: 86 (23%)subjects were treated: 73 with recombinant interferon alone and 13 with pegylated-interferon and ribavirin. Sustained clearance of hepatitis C virus RNA was observed in 25%of the former, in 92%of the latter and in 9% of untreated cases(p < 0.001). Loss of viraemia was re…

Malemedicine.medical_specialtyAdolescentGenotypeCombination therapyHepatitis C virusNatural historyCHILDRENHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsTHERAPYPolyethylene Glycolschemistry.chemical_compoundChronic hepatitisHepatitis C virus RNAInternal medicineRibavirinmedicineHumansChildRetrospective StudiesHepatologyHepatitis C virusbusiness.industryRibavirinGastroenterologyInfantInterferon-alphaCHRONIC HEPATITISHepatitis C ChronicRecombinant ProteinsTreatmentNatural historyClinical PracticeSustained virological responseChildren; Hepatitis C virus; Natural history; Sustained virological response; TreatmentchemistryViral replicationChild PreschoolHCVImmunologyRNA ViralDrug Therapy CombinationFemaleInterferonsbusinessDigestive and Liver Disease
researchProduct

Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy

2021

Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. Aim: To report the use of phylogenetic analysis in the clinical risk management of an HCV outbreak among 128 thalassaemia outpatients followed at a thalassaemia centre of an Italian hospital. Methods: Epidemiological investigation and root-cause analysis were performed. All patients with acute hepatitis and known chronic infection were tested for HCV RNA, HCV genotyping, and NS3, NS5A, and NS5B HCV genomic region sequencing. To identify transmission clusters, phylogenetic trees were built for each…

SofosbuvirClinical risk management Hepatitis C virus (HCV) Molecular epidemiology Nosocomial outbreak Phylogenetic analysis Antiviral Agents Bayes Theorem Disease Outbreaks Genotype Hepacivirus Humans Italy Phylogeny Risk Management Hepatitis C ThalassemiaHepacivirusHepacivirus030501 epidemiologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeDisease OutbreaksSettore MED/07chemistry.chemical_compoundSettore BIO/13 - Biologia ApplicataEpidemiologyMedicinePhylogenySettore MED/12 - Gastroenterologia0303 health sciencesClinical risk managementPhylogenetic analysisbiologyTransmission (medicine)virus diseasesGeneral MedicineHepatitis CHepatitis C virus (HCV)Hepatitis CInfectious DiseasesItalyMolecular epidemiologyThalassemia0305 other medical sciencemedicine.drugMicrobiology (medical)Ledipasvirmedicine.medical_specialtyGenotypeHepatitis C virusAntiviral Agents03 medical and health sciencesPhylogenetic analysiInternal medicineHumansRisk Management030306 microbiologybusiness.industryNosocomial outbreakBayes Theorembiology.organism_classificationmedicine.diseasedigestive system diseasesChronic infectionchemistrybusiness
researchProduct

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women

2014

AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virolo…

Time FactorsViral HepatitisClinical Trials StudyHepacivirusViral hepatitiPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundPegylated interferonOdds RatioMultivariate AnalysiPegylated InterferonGastroenterologyGeneral MedicineHepatitis CHepatitis c virus treatmentMiddle AgedRecombinant ProteinViral LoadGenotype 1Recombinant ProteinsMenopauseTreatment OutcomeItalyRNA ViralDrug Therapy CombinationFemaleMenopauseViral hepatitisViral loadPegylated interferonHumanmedicine.drugmedicine.medical_specialtyGenotypeLogistic ModelProlineTime FactorInterferon alpha-2Hepatitis C virus treatmentAntiviral AgentsPharmacotherapyInternal medicineBoceprevirRibavirinmental disordersmedicineHumansAntiviral AgentHepacivirubusiness.industryInterferon-alphaBiomarkerGenotype 1; Hepatitis c virus treatment; Menopause; Pegylated interferon; Viral hepatitis; Antiviral Agents; Biomarkers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Logistic Models; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; RNA Viral; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Menopause; GastroenterologyHepatitis C Chronicmedicine.diseaseVirologyLogistic ModelschemistryHepatitis C Virus PositiveMultivariate AnalysisGenotype 1; Hepatitis C virus treatment; Menopause; Pegylated Interferon; Viral HepatitisbusinessBiomarkers
researchProduct

Regulation of the Transferrin Receptor Recycling in Hepatitis C Virus-Replicating Cells

2020

After binding of its ligand transferrin, the transferrin receptor (TfR) is internalized via early endosomes. Ligand and receptor can be recycled. α-Taxilin was identified as an essential factor for TfR recycling. Apart from its role for iron uptake, TfR is a coreceptor for hepatitis C virus (HCV) infection. In HCV-replicating cells, the amount of a-taxilin is decreased. This study aims to investigate the effect of decreased α-taxilin levels in HCV-replicating cells on recycling of TfR, its amount on the cell surface, on iron uptake, and the impact of a disturbed TfR recycling on HCV superinfection exclusion. TfR amount and localization were determined by CLSM and surface biotinylation. α-ta…

hepatitis C virus0301 basic medicineEndosomemedia_common.quotation_subjectTransferrin receptorSuperinfection exclusionCell and Developmental Biology03 medical and health sciences0302 clinical medicineiron metabolismInternalizationReceptorlcsh:QH301-705.5iron metabolism ; transferrin receptor ; α-taxilin ; HCV superinfection ; Hepatitis C ; hepatitis C virusOriginal Researchmedia_commonchemistry.chemical_classificationα-taxilinHCV superinfectionvirus diseasesCell Biologytransferrin receptorLigand (biochemistry)Cell biology030104 developmental biologylcsh:Biology (General)chemistryTransferrin030220 oncology & carcinogenesisIntracellularDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct

Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain.

2018

medicine.medical_specialtyHepatologyWaiting Listsbusiness.industrymedicine.medical_treatmentHepatitis C virusAdministration OralLiver transplantationHepatitis C Chronicmedicine.disease_causeAntiviral AgentsLiver Transplantation03 medical and health sciences0302 clinical medicineWaiting list030220 oncology & carcinogenesisInternal medicineMedicineHumans030211 gastroenterology & hepatologyDelisting Direct-acting oral antivirals Hepatitis C virus Liver transplantation Organ allocation WaitlistingbusinessJournal of hepatology
researchProduct